WASHINGTON – The government ended a 14-year virtual ban on silicone-gel breast implants Friday despite lingering safety questions, making the devices available to tens of thousands of women who have clamored for them.
The Food and Drug Administration approved the implants for women 22 and older, or those undergoing breast reconstruction surgery, but warned that patients probably would need at least one additional operation because the implants don’t last a lifetime.
The decision clears implants made by two California manufacturers, Inamed Corp. – now part of Allergan Inc. – and Mentor Corp.
“There is reasonable assurance that Allergan and Mentor silicone-gel breast implants are safe and effective, and there is adequate information to enable women to make informed decisions,” said Dr. Daniel Schultz, the FDA’s medical device chief.
Mentor called the decision a “historic moment.” Allergan said it created new options for women.
However, Dr. Sidney Wolfe, a longtime opponent, called the implants “the most defective medical device FDA has ever approved.” And a lawmaker called on Congress to investigate the FDA’s approval process.
The twin approvals came with conditions, including a requirement that the companies complete 10-year studies on women who have already received the implants to study leaks, as well as begin new decade-long studies of the safety of the devices in 40,000 women. The FDA set the age minimum because women’s breasts aren’t fully developed before then.
Schultz called the implants “one of the most extensively studied medical devices.”
The FDA warned that the implants are not without risk and that women may not immediately know if their implants break. That means women with the implants will need to undergo regular MRIs to catch those so-called “silent ruptures.” Such MRIs typically cost several hundred dollars – a cost not always covered by insurance.
Patients will have to be given special brochures that explain these risks.
Talk to us
> Give us your news tips.
> Send us a letter to the editor.
> More Herald contact information.